EN2105: 11th Annual Virtual Comprehensive Hematology and Oncology Review Course

Instructions

Date & Location
Monday, September 21, 2020, 12:00 AM - Sunday, October 31, 2021, 11:59 PM

Overview

COURSE DESCRIPTION

Due to COVID-19, this year the course will be offered virtually as a library of pre-recorded videos. Registered participants will be provided with login details to access the videos and course material at their own pace. The course will be available online starting September 21, 2020.

This educational program will cover data supporting guidelines, recommendations, and recent advances regarding therapeutic options for patients with solid tumors and malignant and benign hematologic disorders. On completing this program, learners will have a deeper understanding of the pathogenesis, diagnostic evaluation, and therapeutic modalities available for a breadth of solid tumors and hematologic disorders. Learners will also be provided with course material and self-assessment for CME and MOC credits.

COURSE OBJECTIVES

Upon completion of this activity, attendees should be able to:

  • Define the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common malignant hematological diseases.
  • Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common solid tumor malignancies.
  • Integrate guideline-based treatments into clinical practice while personalizing care appropriately for the patient.
  • Incorporate new therapeutic and diagnostic approaches into clinical practice as appropriate.

METHOD OF PARTICIPATION

In order to complete this training, access to the internet and a computer is required. You must receive a minimum passing score of 80% on the post-test (max. 3 attempts) in order to receive your CME credit. Each module will have a required pre-test, educational component, and post-test. 

DATE

Date of Original Release: September 21, 2020

Termination Date: October 30, 2021

Registration will close for this online education on June 1, 2021. Users have until the accreditation term ends on October 30, 2021 to complete the selected module(s).

POST-TEST/EVALUATION

In order to receive CME credit, an 80% pass rate is required. If after three (3) attempts you are unsuccessful, you will be ineligible to receive CME credit for the module. However, content will always be available to you. It is important to know that once you have started the Post-Test (Examination), if you exit the Post-Test without responding to all questions, it will be counted as a failed attempt. Only three (3) attempts are permitted.

TECHNICAL REQUIREMENTS

Minimum browser requirements for successful access and completion for this activity are as follows:

Chrome version 70.0 or newer | Firefox version 63.0 or newer 

FACULTY & DISCLOSURES

The following course planners have disclosed the following:

  • Andrew Coveler, MD (Course Co-Chair/Planner/Reviewer/Speaker): no relevant financial relationships to disclose
  • Ryan Cassaday, MD (Course Co-Chair/Planner/Reviewer/Speaker): Honoraria/Consulting/Teaching: Amgen, Pfizer; Grant/Research Support: Amgen, Merck, Kite/Gilead, Pfizer, Vanda Pharmaceuticals; Major Stock Shareholder: Seattle Genetics
  • David Zhen, MD (Course Reviewer/Speaker): no relevant financial relationships to disclose

Speaker disclosures will be listed within each module. You may also view all speaker disclosures by clicking here.

CONTACT

Seattle Cancer Care Alliance

Continuing Medical Education

[email protected] 

HELP SECTION

Registered users may refer to this USER GUIDE for assistance with navigating through the website. 


Registration
 



Comprehensive Track Oncology Only Track Hematology Only Track
Physician $950.00 $ 750.00 $ 575.00
SCCA/UW/FH/SC/SCCA Network Affiliate Physician $800.00 $ 650.00 $ 475.00
Resident/Fellow $650.00 $ 525.00 $ 400.00
Allied Health Professional $650.00 $ 525.00 $ 400.00
Industry Professional $950.00 $ 750.00 $ 575.00

The fee for this course includes access to online materials and transcript of AMA PRA Category 1 Credits™ and MOC. To ensure enrollment in the course, please register online HERE.

Industry Professional: register at this rate if you are affiliated with a pharmaceutical company, device manufacturer or a healthcare education/communications company.


Additional Information

Enduring Material Content

*Note - you must register for the main activity (EN2105) above in order to receive access to view the content.

 

 Section I  Thoracic, Head and Neck Oncology
 EN2105MM  NSCLC - Adjuvant/Locally Advanced by Rafael Santana-Davila, MD
 EN2105GG  Metastatic Non-Small Cell Lung Cancer by Christina Baik, MD, MPH
 EN2105MO  Small Cell Lung Cancer: The Basics by Rafael Santana-Davila, MD
 EN2105DD  Head and Neck Cancer by Cristina Rodriguez, MD
 EN2105W  Malignant Pleural Mesothelioma by Bernardo Goulart, MD, MS
   
 Section II  Breast Oncology
 EN2105VV  Therapy for Non-Invasive Breast Cancer and Prevention by Rachel Yung, MD
 EN2105BB  Adjuvant Therapy for Breast Cancer by William Gwin, MD
 EN2105AA  Metastatic Breast Cancer by Natasha Hunter, MD
   
 Section III  GI Oncology
 EN2105LL  Esophageal and Gastric Cancer by Veena Shankaran, MD, MS
 EN2105FF  Biliary Tract Cancers by David Zhen, MD
 EN2105TT  Hepatocellular Carcinoma by William P. Harris, MD
 EN2105RR  Pancreas Cancer by Gabriela Chiorean, MD
 EN2105NN  Colorectal Cancer - Adjuvant by Stacey Cohen, MD
 EN2105NO  Colorectal Cancer - Metastatic by Stacey Cohen, MD
 EN2105Y  Anal Cancer by Andrew Coveler, MD
 EN2105EE  Gastroenteropancreatic Neuroendocrine Tumors by Kaylyn Kit Man Wong, MD
   
 Section IV  GU Oncology
 EN2105SS  Prostate Cancer by Tanya Dorff, MD
 EN2105QQ  Testicular Cancer by Todd Yezefski, MD
 EN2105UU  Systemic Therapy in the Treatment of Bladder Cancer by Michael Schweizer, MD
   
 Section V  Gynecologic Oncology
 EN2105CC  Endometrial and Cervical Cancers by Kathryn Pennington, MD
 EN2105OO  Updates in Ovarian Cancer by Renata R. Urban, MD
   
 Section VI  Other Malignancies: Renal, Melanoma, CNS, Sarcoma
 EN2105JJ  CNS Cancers by Vyshak Venur, MD
 EN2105KK  Renal Cell Carcinoma by Scott Tykodi, MD, PhD
 EN2105II  Sarcoma Board Review 2020 by Seth Pollack, MD
 EN2105X  Melanoma and Other Skin Cancers by Shailender Bhatia, MD
   
 Section VII  Lymphomas
 EN2105C  Indolent Non-Hodgkin Lymphoma: 2020 by Solomon Graf, MD
 EN2105L  Aggressive B-Cell Non-Hodgkin Lymphomas by Stephen Smith, MD
 EN2105E  Hodgkin Lymphoma by Ryan Lynch, MD
 EN2105V  Peripheral T-Cell Lymphomas by Andrei Shustov, MD
   
 Section VIII  Leukemia and Myelomas
 EN2105K  Acute Myeloid Leukemia in 2020 by Mary-Beth Percival, MD
 EN2105A   Acute Lymphoblastic Leukemia in Adults by Ryan Cassaday, MD
 EN2105J  Chronic Myeloid Leukemia in 2020 by Vivian Oehler, MD
 EN2105F  Chronic Lymphocytic Leukemia and Hairy Cell Leukemia by Mazyar Shadman, MD, MPH
 EN2105H  Monoclonal Gammopathies and Multiple Myeloma by Edward Libby, MD
 EN2105B  Management of Multiple Myeloma: Board Review by Andrew Cowan, MD
   
 Section IX  Hematology
 EN2105S  Inherited and Acquired Marrow Failure by Sioban Keel, MD
 EN2105I  Benign White Cell Disorders by Michael Linenberger, MD
 EN2105G  Myeleoproliferative Neoplasms by Anna Halpern, MD
 EN2105N  The Myelodysplastic Syndromes by Aaron T. Gerds, MD, MS
 EN2105M  Iron Metabolism Disorders and Hemolytic Anemias by Kleber Fertrin MD, PhD
 EN2105P  Hemoglobin Disorders by Kleber Fertrin, MD, PhD
 EN2105O  Thrombotic Microangiopathies (TTP/HUS) by Allyson Pishko, MD, MSCE
 EN2105R  Thrombocytopenia: Updated Review by Terry Gernsheimer, MD
 EN2105T  Bleeding Disorders by Rebecca Kruse-Jarres, MD, MPH
 EN2105U  Hematopoietic Stem Cell Transplantation by Rachel Salit, MD
 EN2105D  Transfusion Medicine by Jill Johnsen, MD
 EN2105Q  Update in Venous Thromboembolism by David Garcia, MD
   
 Section X  Other Topics: Pharmacology I and II, ID Complications, Integrative Medicine, Hereditary Cancer Syndromes, and   Radiation Oncology
 EN2105WW
  Supportive Care by Keith Eaton, MD, PhD
 EN2105XX
  Integrative Oncology - What Oncology Clinicians Need to Know by Heather Greenlee, ND, PhD, MPH
 EN2105HH  Hereditary Cancer Syndromes by Cynthia Handford, MSc, LCGC
 EN2105ZZ  Infections in Cancer and HCT Recipients by Steven Pergam, MD, MPH
 EN2105Z  Cancer Pharmacology I by Zakary Cerminara, PharmD, BCOP
 EN2105YY
  Cancer Pharmacology II by Amy Indorf, PharmD, BCOP
 EN2105PP  General Principles of Radiation Oncology by Jonathan Chen, MD, PhD
      

Accreditation

Comprehensive Package: 36.75 hours

The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Washington School of Medicine designates this enduring material for a maximum of 36.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Medical Oncology Package: 29 hours

The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Washington School of Medicine designates this enduring material for a maximum of 29 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Hematology Package: 20.75 hours

The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Washington School of Medicine designates this enduring material for a maximum of 20.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

MAINTENANCE OF CERTIFICATION (MOC) CREDITS: COMPREHENSIVE PACKAGE

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 36.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MAINTENANCE OF CERTIFICATION (MOC) CREDITS: MEDICAL ONCOLOGY PACKAGE

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 29 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MAINTENANCE OF CERTIFICATION (MOC) CREDITS: HEMATOLOGY PACKAGE

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 20.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Keywords: